2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1447 TRIM28 maintains acute myeloid leukemia cell survival by establishing a transcriptional program that restrains ferroptotic vulnerability

Yiyang Xu, Yabin Liu2, Yun Tan, PhD3
1 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background:
Acute myeloid leukemia (AML) cells are exposed to substantial oxidative, metabolic, and iron-associated stress, yet the transcriptional mechanisms that enable leukemia cells to evade ferroptotic cell death remain incompletely understood. Tripartite motif-containing protein 28 (TRIM28) is a multifunctional transcriptional coregulator and chromatin-associated protein involved in gene silencing, heterochromatin organization, and cellular stress responses. However, its functional requirement and mechanistic role in AML have not been fully defined.

Results:
Using shRNA-mediated knockdown in human AML cell lines, we found that TRIM28 depletion markedly impaired cellular proliferation and reduced leukemia cell viability, identifying TRIM28 as a functional dependency in AML. Electron microscopy, oxidative stress measurements, and lipid peroxidation assays demonstrated that TRIM28-deficient cells developed prominent features consistent with ferroptotic stress, including mitochondrial structural abnormalities, increased oxidative injury, and enhanced lipid peroxidation. These findings indicate that ferroptotic vulnerability represents an important consequence of TRIM28 depletion in AML cells. Moreover, TRIM28 knockdown enhanced the antileukemic activity of venetoclax, suggesting that the TRIM28-regulated adaptive program limits venetoclax sensitivity and that targeting TRIM28 may improve therapeutic response.
To define the underlying regulatory mechanism, we integrated RNA sequencing with TRIM28 chromatin immunoprecipitation sequencing. These analyses revealed that TRIM28 controls a broad transcriptional network involved in redox homeostasis, iron handling, lipid metabolism, mitochondrial function, and cellular stress adaptation. TRIM28 depletion disrupted this protective gene-expression state and shifted AML cells toward a ferroptosis-prone phenotype. Chromatin occupancy analysis identified a subset of dysregulated genes as candidate direct TRIM28 targets, supporting a model in which TRIM28 restrains ferroptotic vulnerability through a chromatin-associated transcriptional program rather than through a nonspecific effect on cell viability.
To evaluate the therapeutic tractability of TRIM28, we performed a DNA-encoded library screen and identified candidate small-molecule compounds targeting TRIM28. Selected compounds reduced TRIM28 expression and decreased AML cell viability, thereby phenocopying key effects of shRNA-mediated TRIM28 knockdown. These findings provide initial pharmacologic evidence that TRIM28 represents a potentially actionable dependency in AML.

Conclusions:
Our findings identify TRIM28 as a previously underappreciated transcriptional safeguard against ferroptotic vulnerability in AML. TRIM28 establishes a chromatin-associated transcriptional program that supports redox and lipid homeostasis, thereby enabling leukemia cells to tolerate iron-associated oxidative and metabolic stress. TRIM28 knockdown disrupts this adaptive state, promotes oxidative injury and lipid peroxidation, increases ferroptotic vulnerability, enhances venetoclax sensitivity, and suppresses AML cell growth. The identification of candidate TRIM28-targeting small molecules further supports the therapeutic tractability of this dependency and provides a rationale for developing TRIM28-directed strategies, either alone or in combination with venetoclax, for the treatment of AML.

Yiyang Xu: No relevant conflicts of interest to declare.